However, the response rate to anti-EGFR target therapy in HER2-positive BC could be also influenced by the ER status, being lower in ER(+) as compared to ER(−) patients independently from the kind of target chemotherapy schedule performed [35,36,37]. The gene discussed is EGFR; the disease is breast cancer.